receives
notice
allowance
strategic
patent
prexigebersen
combination
front
line
cytidine
analogues
tyrosine
kinase
inhibitors
variety
cancers
houston
globe
newswire
holdings
nasdaq
bpth
biotechnology
company
leveraging
proprietary
liposomal
delivery
antisense
technology
develop
portfolio
targeted
nucleic
acid
cancer
drugs
today
announced
united
states
patent
trademark
office
issued
notice
allowance
claims
related
company
lead
product
candidate
prexigebersen
combination
either
cytidine
analogue
decitabine
tyrosine
kinase
inhibitors
dasatinib
nilotinib
prexigebersen
liposomal
formulation
containing
antisense
oligodeoxynucleotide
targeting
growth
factor
protein
new
patent
titled
combination
therapy
liposomal
antisense
oligonucleotides
based
application
provide
broad
protection
application
prexigebersen
treatment
variety
cancers
combination
therapies
strengthens
intellectual
property
portfolio
complements
already
granted
patents
growing
patent
estate
continues
valuable
asset
provides
protection
core
product
portfolio
research
efforts
also
offers
broad
protection
combination
established
therapies
said
peter
nielsen
president
chief
executive
officer
holdings
currently
ongoing
phase
clinical
trial
prexigebersen
combination
decitabine
treatment
acute
myeloid
leukemia
aml
new
patent
protects
unique
therapy
combination
supports
ongoing
investment
program
bring
new
treatment
option
patients
aml
limited
treatment
options
added
nielsen
holdings
biotechnology
company
developing
novel
technology
yielded
pipeline
rnai
nanoparticle
drugs
administered
simple
intravenous
transfusion
lead
product
candidate
prexigebersen
targeting
protein
phase
study
blood
cancers
consideration
fda
commence
phase
studies
solid
tumors
followed
targeting
protein
evaluated
lymphoma
chronic
lymphocytic
leukemia
cll
third
product
finalizing
ind
evaluated
solid
tumor
clinical
studies
information
please
visit
company
website
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
federal
securities
laws
statements
based
management
current
expectations
accordingly
subject
uncertainty
changes
circumstances
express
implied
statements
contained
press
release
statements
historical
fact
may
deemed
statements
statements
historical
facts
contained
release
statements
involve
risks
uncertainties
including
impact
risks
uncertainties
related
actions
taken
governmental
authorities
others
connection
therewith
ability
raise
needed
additional
capital
timely
basis
order
continue
operations
ability
success
clinical
development
technologies
timing
enrollment
release
data
clinical
studies
accuracy
data
limited
patient
populations
early
stage
clinical
studies
possibility
results
later
stage
clinical
trials
much
larger
patient
populations
may
consistent
earlier
stage
clinical
trials
maintenance
intellectual
property
rights
patents
relating
existing
future
patent
applications
issued
issued
patents
provide
meaningful
protection
drug
candidates
risks
relating
maintaining
listing
nasdaq
capital
market
risks
identified
recent
annual
report
form
subsequent
quarterly
reports
form
reports
files
securities
exchange
commission
time
time
documents
available
request
holdings
disclaims
intention
obligation
update
revise
statements
whether
result
new
information
future
events
otherwise
contact
information
investors
connor
stern
investor
relations
doug
morris
investor
relations
holdings
